14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CRMD vs MPLT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas MPLT carries 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. MPLT 50.4/100 HOLD) and 1.20β · 107% Vol risk profile, whereas MPLT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs MPLT. Trailing 12-month operating profitability (CRMD 41.0% vs MPLT 0.0%) and valuation multiples (CRMD 49.0x vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $392.9M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CRMD vs MPLT Key Questions & Quantitative Answers
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CRMD carries a Unified Composite Score of 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin), whereas MPLT carries 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. MPLT 50.4/100 HOLD) and 1.20β · 107% Vol risk profile, whereas MPLT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CRMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3); meanwhile MPLT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CRMD leads the Growth & Scale pillar: CRMD posts -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin), compared with MPLT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CRMD generates $1.05B in USD-normalized revenue versus N/A for MPLT. In operating R&D and SG&A reinvestment, CRMD deploys 46.4% of Rev ($488M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MPLT.
CRMD screens cheaper on headline valuation multiples. CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin), whereas MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRMD (15.3% ROE) versus MPLT (-111.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk). By comparison, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.